The Pros and Cons of Using Point-of-Care D-Dimer Testing in the Diagnosis of Deep Vein Thrombosis

Introduction

Deep vein thrombosis (DVT) is a serious medical condition caused by the formation of blood clots in the deep veins, most commonly in the legs. If left untreated, DVT can result in major complications such as pulmonary embolism (PE), post-thrombotic syndrome, and chronic venous insufficiency. Early and accurate diagnosis is therefore essential to prevent morbidity and mortality.

Diagnosing DVT can be challenging because symptoms such as leg pain, swelling, redness, and tenderness are often non-specific. Many patients with suspected DVT do not actually have thrombosis, while some patients with minimal symptoms may harbour clinically significant clots. For this reason, clinicians typically combine clinical assessment tools, laboratory investigations, and imaging studies when evaluating patients with suspected venous thromboembolism (VTE).

One of the most widely used laboratory investigations is the D-dimer test. D-dimer is a degradation product formed when fibrin clots are broken down in the body. Elevated D-dimer levels indicate activation of coagulation and fibrinolysis, which commonly occurs in thrombotic disease. Traditionally, D-dimer testing has been performed in hospital laboratories, but technological advances have enabled the development of point-of-care (POC) D-dimer tests that can provide rapid bedside results.

Point-of-care D-dimer testing has become increasingly popular in emergency departments, urgent care centres, primary care practices, and rural healthcare settings because it offers rapid diagnostic information. However, despite its convenience, important concerns remain regarding diagnostic accuracy, false results, quality control, and appropriate clinical use.

This article explores the advantages and disadvantages of using point-of-care D-dimer testing in the diagnosis of deep vein thrombosis.

Understanding Point-of-Care D-Dimer Testing

D-dimer testing is mainly used as a “rule-out” test rather than a confirmatory test. A negative D-dimer result in a patient with a low clinical probability of DVT can effectively exclude thrombosis and reduce the need for imaging studies such as compression ultrasonography.

Point-of-care D-dimer assays are portable diagnostic tests designed to provide rapid results near the patient rather than in a central laboratory. Results are typically available within 10–20 minutes. These tests may be qualitative, semi-quantitative, or quantitative.

Research comparing POC assays with conventional laboratory testing has shown that point-of-care tests generally have slightly lower sensitivity but somewhat higher specificity than laboratory-based assays. NICE evidence reviews reported overall sensitivities of approximately 88% for POC tests compared with 93% for laboratory assays, while specificity was around 63% for POC tests versus 48% for laboratory tests. Quantitative point-of-care tests performed substantially better than qualitative tests. (NCBI)

Advantages of Point-of-Care D-Dimer Testing

Rapid Turnaround Time

The most significant advantage of point-of-care D-dimer testing is speed. Traditional laboratory testing may require blood transport, sample preparation, laboratory processing, and electronic reporting, which can delay results by hours.

Point-of-care testing provides results within minutes, enabling faster clinical decision-making. Rapid diagnosis or exclusion of DVT can improve patient flow in busy emergency departments and reduce delays in treatment or discharge.

Faster results also reduce patient anxiety. Patients with suspected thrombosis are often worried about potentially life-threatening complications, and rapid reassurance can significantly improve patient experience.

Improved Access to Diagnostic Testing

Point-of-care testing is especially valuable in settings where laboratory services are limited or unavailable. Rural clinics, primary care offices, ambulances, and urgent care centres may lack immediate access to centralised laboratory facilities.

In these environments, bedside D-dimer testing allows clinicians to evaluate patients more efficiently without transferring every suspected case to a hospital. This can improve healthcare accessibility and reduce unnecessary referrals.

Reviews of point-of-care diagnostics have highlighted the usefulness of decentralised testing in remote and resource-limited healthcare systems. (NCBI)

Reduction in Unnecessary Imaging

Compression ultrasonography is considered the standard imaging modality for diagnosing DVT, but routine imaging of all patients with leg symptoms is expensive and resource intensive.

When combined with validated clinical prediction rules such as the Wells score, a negative point-of-care D-dimer test can safely exclude DVT in many low-risk patients. This reduces unnecessary ultrasound examinations and decreases pressure on radiology departments.

Reducing imaging demand is particularly beneficial during weekends, overnight periods, or in healthcare systems with limited radiology resources.

Improved Workflow Efficiency

Point-of-care testing integrates easily into bedside clinical assessment. Clinicians can evaluate symptoms, calculate pre-test probability, and obtain D-dimer results during the same patient encounter.

This streamlined process improves operational efficiency and shortens patient waiting times. Patients with negative results and low-risk clinical scores can often be discharged quickly, while high-risk patients can proceed rapidly to imaging and treatment.

Healthcare systems increasingly prioritise efficient patient pathways, and POC testing supports this objective. If the benefits can be clearly demonstrated then funding is likely to be allocated to implement such as service.

Potential Cost Savings

Point-of-care D-dimer testing may reduce healthcare costs by lowering imaging rates, reducing emergency department length of stay, and minimising unnecessary hospital admissions.

Although POC devices and consumables can be expensive, the reduction in downstream investigations and resource utilisation may offset these costs. Economic benefits are particularly important in healthcare systems facing increasing patient volumes and limited budgets.

Better Patient Convenience

Point-of-care testing can often help complete the diagnostic assessment during a single visit. This is especially useful in ambulatory and outpatient settings where repeated appointments create inconvenience for patients.

Rapid bedside testing also improves communication between clinicians and patients because diagnostic decisions can be discussed immediately.

Disadvantages of Point-of-Care D-Dimer Testing

Lower Sensitivity Compared with Laboratory Testing

One of the main concerns regarding point-of-care D-dimer testing is reduced sensitivity compared with laboratory-based assays.

Because D-dimer testing is primarily used to exclude DVT, high sensitivity is essential. False negative results may lead to missed diagnoses, delayed treatment, pulmonary embolism, or death.

Evidence reviews have shown that POC assays generally demonstrate slightly lower sensitivity than laboratory tests overall. Qualitative POC assays appear particularly vulnerable to lower sensitivity, with some studies reporting sensitivity as low as 85%, compared with approximately 97% for quantitative assays. (NCBI)

This variation means that not all point-of-care tests are equally reliable and therefore, rigorous validation and verification of the methodology is required before adoption.

Poor Specificity and False Positive Results

D-dimer is highly sensitive but poorly specific for thrombosis. Elevated D-dimer levels occur in many conditions unrelated to DVT, including:

Infection, Inflammation, Cancer, Pregnancy, Trauma, Surgery, Liver disease, Increasing age. As a result, many patients with elevated D-dimer levels do not actually have thrombosis.

False positive results can lead to unnecessary ultrasound examinations, hospital referrals, anticoagulation therapy, patient anxiety, and increased healthcare expenditure.

This limitation becomes particularly problematic in elderly patients and hospitalised individuals who commonly have elevated D-dimer levels for reasons unrelated to thrombosis.

Variability Between Different Assays

Point-of-care D-dimer assays are not fully standardised. Different manufacturers use different technologies, antibodies, thresholds, and reporting units. Some devices are sophisticated quantitative analysers with high sensitivity, while others are simpler qualitative tests with lower accuracy.

This lack of standardisation can create confusion for clinicians and complicate implementation of uniform diagnostic guidelines. NICE reviews noted significant heterogeneity between studies evaluating different point-of-care assays. (NCBI)

Dependence on Clinical Probability Assessment

D-dimer results must always be interpreted in the context of clinical probability.

Clinical decision rules such as the Wells score are essential because the usefulness of D-dimer testing depends heavily on pre-test probability. In patients with high clinical suspicion of DVT, a negative D-dimer result may not safely exclude thrombosis.

Improper reliance on D-dimer testing without appropriate clinical assessment can increase diagnostic errors. Clinicians frequently emphasise that D-dimer interpretation without consideration of pre-test probability can be misleading.

Quality Control and Operator Dependency

Unlike centralised laboratory testing, point-of-care assays are often performed by nurses, physicians, or healthcare assistants rather than trained laboratory personnel.

This creates challenges related to:

• Operator training
• Inventory management
• Sample collection
• Device calibration
• Quality assurance
• Maintenance procedures

Errors in sample handling or device operation may compromise diagnostic accuracy.

Reduced Usefulness in Certain Patient Groups

The diagnostic value of D-dimer testing is reduced in several populations.

Elderly Patients

D-dimer levels naturally increase with age, resulting in frequent false positive results. Although age-adjusted thresholds improve specificity, not all point-of-care systems incorporate validated age-adjusted algorithms.

Patients with Cancer

Malignancy causes chronic activation of coagulation pathways, leading to persistently elevated D-dimer levels. Clinicians often prefer direct imaging in cancer patients with suspected thrombosis.

Discussions among physicians highlight uncertainty regarding the usefulness of D-dimer testing in patients with active malignancy.

Pregnant Patients

Pregnancy physiologically elevates D-dimer levels, limiting specificity and reducing diagnostic utility.

Hospitalised and Postoperative Patients

Inflammation, surgery, infection, and immobility commonly elevate D-dimer levels independent of thrombosis.

Risk of Overuse

Because point-of-care testing is convenient and rapid, clinicians may overuse the test in situations where it is unlikely to influence management. Indiscriminate D-dimer testing increases false positive results and may paradoxically increase unnecessary imaging.

Appropriate patient selection remains essential.

The Importance of Clinical Decision Rules

The effectiveness of point-of-care D-dimer testing depends heavily on integration with validated clinical prediction models such as the Wells score.

Patients are usually classified into low, moderate, or high probability categories. In low-risk patients, a negative D-dimer result can safely exclude DVT without imaging. In high-risk patients, imaging is generally required regardless of D-dimer findings.

Combining clinical probability assessment with D-dimer testing improves diagnostic accuracy while minimising unnecessary investigations. Without clinical context, D-dimer testing alone is insufficient for safe decision-making.

Conclusion

Point-of-care D-dimer testing offers several important advantages in the diagnosis of deep vein thrombosis as discussed above.

However, significant limitations remain. Point-of-care assays may have lower sensitivity than laboratory-based tests, especially when qualitative methods are used. False positive results remain common because D-dimer lacks specificity for thrombosis. Additional concerns include variability between assays, operator dependency, quality control challenges, and reduced usefulness in elderly patients, cancer patients, and pregnancy.

Ultimately, point-of-care D-dimer testing should be viewed as an adjunct to clinical assessment rather than a standalone diagnostic tool. Its safest and most effective use occurs when integrated with validated clinical prediction rules and evidence-based diagnostic pathways.

As newer quantitative assays continue to improve, point-of-care D-dimer testing may play an increasingly important role in rapid thrombosis assessment. Nevertheless, clinicians must remain aware of both its strengths and limitations to ensure safe and accurate diagnosis of deep vein thrombosis. (NCBI)